Hard To Treat Diseases (HTDS) Mellow Hope's H1N1 Influenza A Vaccine Successful Registration in Chile

SHENZHEN, China, November 18 - Hard to Treat Diseases (HTDS; www.htdsmedical.com) and its China
subsidiary Mellow Hope announce that they have acquired a Registration
Certificate for Mellow Hope's H1N1 Influenza A Vaccine from the government
of Chile and the first vaccines will ship in a matter of weeks.

Chile's Institute of Public Health (ISP) (www.ispch.cl) issued
the Registration Certificate for Mellow Hope's H1N1 Influenza A Vaccine
(Virion Split). Mellow Hope's H1N1 vaccine is also the first such type of
license in Chile. Mellow Hope is also the first China-based company to
acquire the H1N1 vaccine approval from a foreign country. The management of
HTDS sees this achievement as a "leg up" on the competition which gives
Mellow Hope a significant advantage in South American markets for future
expansions.

HTDS' CEO Terry Yuan said, "We think this is a great start of our South
American expansion which dates back to March of this year. We see this as a
tremendous boost to our South American efforts to market our H1N1 vaccine in
that region. The optimism of the Chilean negotiations provides us with a
great advantage and helps us to promote the export of our H1N1 vaccine to
other South American countries. This competitive edge should speed up our
registration progress with other South American authorities, securing our
place in these markets."

Hard to Treat Diseases (HTDS) operates two medical subsidiaries in Europe
and Mainland China. HTDS is a parent company with operations in Eastern
Europe Serbia-based pharmaceutical company Slavica Bio Chem Co. and in China
Mellow Hope Inc.

The initial order and dollar sums will be shortly released; however, they
are significant.

To receive future updates via email, including quarterly newsletters and
company updates that may not be newsworthy, however important to the reader
and followers of the company, please sign up today free at
www.minamargroup.com/updates.

Safe Harbor Statement

Information in this news release may contain statements about future
expectations, plans, prospects or performance of Hard to Treat Diseases Inc.
that constitute forward-looking statements for purposes of the Safe Harbor
Provisions under the Private Securities Litigation Reform Act of 1995. The
words or phrases "can be", "expects", "may affect", "believed", "estimate",
"project" and similar words and phrases are intended to identify such
forward-looking statements. Hard to Treat Diseases Inc. cautions you that
any forward-looking information provided by or on behalf of Hard to Treat
Diseases Inc. is not a guarantee of future performance. None of the
information in this press release constitutes or is intended as an offer to
sell securities or investment advice of any kind. Hard to Treat Diseases
Inc.'s actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important factors, some of
which are beyond Hard to Treat Diseases Inc.'s control. In addition to those
discussed in Hard to Treat Diseases Inc.'s press releases, public filings,
and statements by Hard to Treat Diseases Inc.'s management, including, but
not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of
its existing capital resources, Hard to Treat Diseases Inc.'s ability to
raise additional capital to fund future operations, Hard to Treat Diseases
Inc.'s ability to repay its existing indebtedness, the uncertainties
involved in estimating market opportunities, and in identifying contracts
which match Hard to Treat Diseases Inc.'s capability to be awarded contracts.
All such forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases Inc. does not undertake
any obligation to publicly update any forward-looking statement to reflect
events or circumstances after the date on which any such statement is made
or to reflect the occurrence of unanticipated events.

For further information: Jeffrey Allen, +1-647-426-1640; For any investor
relations matters, please contact www.minamargroup.net/helpdesk;
Investor Relations Department Inquiry, www.minamargroup.net (IR);
For (M&A) and Corporate Matters, www.minamargroup.com/

For further information: Jeffrey Allen, +1-647-426-1640